Bacil Pharma Limited
Bacil Pharma Limited Fundamental Analysis
Bacil Pharma Limited (BACPHAR.BO) shows weak financial fundamentals with a PE ratio of 92.83, profit margin of 8.41%, and ROE of 3.74%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 50.1/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze BACPHAR.BO's fundamental strength across five key dimensions:
Efficiency Score
WeakBACPHAR.BO struggles to generate sufficient returns from assets.
Valuation Score
WeakBACPHAR.BO trades at a premium to fair value.
Growth Score
ModerateBACPHAR.BO shows steady but slowing expansion.
Financial Health Score
ExcellentBACPHAR.BO maintains a strong and stable balance sheet.
Profitability Score
WeakBACPHAR.BO struggles to sustain strong margins.
Key Financial Metrics
Is BACPHAR.BO Expensive or Cheap?
P/E Ratio
BACPHAR.BO trades at 92.83 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, BACPHAR.BO's PEG of 7.64 indicates potential overvaluation.
Price to Book
The market values Bacil Pharma Limited at 2.60 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -719.45 times EBITDA. This is generally considered low.
How Well Does BACPHAR.BO Make Money?
Net Profit Margin
For every $100 in sales, Bacil Pharma Limited keeps $8.41 as profit after all expenses.
Operating Margin
Core operations generate -1.37 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $3.74 in profit for every $100 of shareholder equity.
ROA
Bacil Pharma Limited generates $2.77 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Bacil Pharma Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Bacil Pharma Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
BACPHAR.BO converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
92.83
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
7.64
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.60
vs 25 benchmark
P/S Ratio
Price to sales ratio
801.77
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
13.36
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.04
vs 25 benchmark
ROA
Return on assets percentage
0.03
vs 25 benchmark
ROCE
Return on capital employed
-0.00
vs 25 benchmark
How BACPHAR.BO Stacks Against Its Sector Peers
| Metric | BACPHAR.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 92.83 | 29.78 | Worse (Expensive) |
| ROE | 3.74% | 792.00% | Weak |
| Net Margin | 840.71% | -24634.00% (disorted) | Strong |
| Debt/Equity | 0.00 | 0.25 | Strong (Low Leverage) |
| Current Ratio | 13.36 | 4.60 | Strong Liquidity |
| ROA | 2.77% | -18106.00% (disorted) | Weak |
BACPHAR.BO outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Bacil Pharma Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation